Physiology of the blood-brain barrier and its consequences for drug transport to the brain

International Congress Series

Volumn 1277, Issue , 2005, Pages 3-18

  Abbott, N Joan ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Blood brain barrier; Drug delivery; Interstitial fluid; Permeability; Transport

Indexed keywords

EID: 33646450620     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2005.02.008     Document Type: Article

References (50)

1. Lennington J.B., Yang Z., and Conover J.C. Neural stem cells and the regulation of adult neurogenesis. Reprod. Biol. Endocrinol. 1 1 (2003) 99
2. Abbott N.J. Dynamics of CNS barriers: evolution, differentiation and modulation. Cell. Mol. Neurobiol. 25 (2005) 5-23
3. Abbott N.J. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. 5 (2004) 545-552
4. Schlageter K.E., et al. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc. Res. 58 (1999) 312-328
5. Abbott N.J., and Romero I.A. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today 2 (1996) 106-113
6. Begley D.J., and Brightman M.W. Structural and functional aspects of the blood-brain barrier. Prog. Drug Res. 61 (2003) 39-78
7. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104 (2004) 29-45
8. Wolberg H., and Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vasc. Pharmacol. 38 (2002) 323-337
9. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nature Rev. Neurosci. 5 (2004) 347-360
10. Nedergaard M., Ransom B., and Goldman S.A. New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci. 26 10 (2003) 523-530
11. Abbott N.J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 200 (2002) 629-638
12. Nagy Z., Peters H., and Hüttner I. Fracture faces of cell junctions in cerebral endothelium during normal and hyperosmotic conditions. Lab. Invest. 50 (1984) 313-322
13. Bodor N., and Buchwald P. Brain-targeted drug delivery. Experiences to date. Am. J. Drug Deliv. 1 1 (2003) 13-26
14. Krämer S.D., et al. Lipids in blood-brain barrier models in vitro: I. Thin layer chromatography and high performance liquid chromatography for the analysis of lipid classes and long-chain polyunsaturated fatty acids. In Vitro Cell. Dev. Biol. 38A (2002) 557-565
15. Di L., et al. High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 38 (2003) 223-232
16. Simons K., and Vaz W.L. Model systems, lipid rafts, and cell membranes. Ann. Rev. Biophys. and Biomol. Structure 33 (2004) 269-295
17. +-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. J. Biol. Chem. 274 (1999) 31891-31895
18. McAllister M.S., et al. Mechanisms of glucose transport at the blood-brain barrier: an in vitro study. Brain Res. 409 (2001) 20-30
19. Begley D.J. ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 10 (2004) 1295-1312
20. Zlokovic B.V. Clearing amyloid through the blood-brain barrier. J. Neurochem. 89 4 (2004) 807-822
21. Pardridge W.M. Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems. ICS 1277 (2005) 49-62 10.1016/j.ics.2005.02.011 this volume
22. Pan W., Csernus B., and Kastin A.J. Upregulation of p55 and p75 receptors mediating TNF-α transport across the injured blood-spinal cord barrier. J. Mol. Neurosci. 21 2 (2003) 173-184
23. Minn A., et al. Drug metabolism in the brain: benefits and risks. In: Begley D.J., Bradbury M.W., and Kreuter J. (Eds). The blood-brain barrier and drug delivery to the CNS (2000), Marcel Dekker, New York 145-170
24. Chishty M., et al. Functional characterisation of nucleoside transport in rat brain endothelial cells. Neuroreport 14 (2003) 1087-1090
25. Chishty M., et al. Interaction of nucleoside analogues with nucleoside transporters in rat brain endothelial cells. J. Drug Target. 12 (2004) 265-272
26. Isakovic A.J., et al. Brain to blood efflux transport of adenosine: blood-brain barrier studies in the rat. J. Neurochem. 90 (2004) 272-286
27. Mann G.E., Yudilevich D.L., and Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol. Rev. 83 1 (2003) 183-252
28. Pan W., and Kastin A.J. Diurnal variation of leptin entry from blood to brain involving partial saturation of the transport system. Life Sci. 68 24 (2001) 2705-2724
29. Kurrimbux D., et al. The involvement of the blood-brain and the blood-cerebrospinal fluid barriers in the distribution of leptin into and out of the rat brain. Neuroscience 123 2 (2004) 527-536
30. Bénistant C., et al. Fatty acid composition of brain capillary endothelial cells: effect of coculture with astrocytes. J. Lipid Res. 36 (1995) 2311-2319
31. Bernoud N., et al. Astrocytes are mainly responsible for the polyunsaturated fatty acid enrichment in blood-brain barrier endothelial cells in vitro. J. Lipid Res. 39 (1998) 1816-1824
32. Braet K., et al. Calcium signal communication in the central nervous system. Biol. Cell 96 (2004) 79-91
33. Enerson B.E., and Drewes L.R. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J. Pharm. Sci. 92 8 (2003) 1531-1544
34. Ximenes da Silva A., et al. Glucose transport and utilization are altered in the brain of rats deficient in n-3 polyunsaturated fatty acids. J. Neurochem. 81 6 (2002) 1328-1337
35. Sarker M.H., and Fraser P.A. The role of guanyl cyclases in the permeability response to inflammatory mediators in pial venular capillaries in the rat. J. Physiol. 540 1 (2002) 209-218
36. Simard M., et al. Signaling at the gliovascular interface. J. Neurosci. 23 27 (2003) 9254-9262
37. Wolburg H., Wolburg-Buchholz K., and Engelhardt B. Involvement of tight junctions during transendothelial migration of mononuclear cells in experimental autoimmune encephalomyelitis. Ernst Schering Res. Found. Workshop 47 (2004) 17-38
38. Abbott N.J. Prediction of blood-brain barrier permeation from in vivo, in vitro and in silico models. Drug Discov. Today: Technologies 1 (2004) 407-416
39. Mahar Doan K.M., et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303 3 (2002) 1029-1037
40. Sherrmann J.-M., and Temsamani J. The use of Pep:Trans vectors for the delivery of drugs into the central nervous system. ICS 1277 (2005) 199-211 10.1026/j.ics.2005.02.023 this volume
41. Kreuter J. Application of nanoparticles for the delivery of drugs to the brain. ICS 1277 (2005) 85-94 10.1026/j.ics.2005.02.014 this volume
42. Plumb J., et al. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol. 12 (2002) 154-169
43. McAllister L.D., et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46 1 (2000) 51-60
44. Tomkins O., et al. Frequent blood-brain barrier disruption in the human cerebral cortex. Cell. Mol. Neurobiol. 21 6 (2001) 675-691
45. E. Seiffert, et al., Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex, J. Neurosci. 24 (35) (in press).
46. Yarnitsky D., et al. Blood-brain barrier opening by parasympathetic sphenopalatine ganglion stimulation: a new method for macromolecule delivery to the brain. J. Neurosurg. 101 (2004) 303-309
47. Werring D.J., et al. The pathogenesis of lesions and normal appearing white matter changes in multiple sclerosis, a serial diffusion MRI study. Brain 123 (2000) 1667-1676
48. Minagar A., and Alexander J.S. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 9 6 (2003) 540-549
49. Marroni M., et al. Vascular and parenchymal mechanisms in multiple drug resistance: a lesson from human epilepsy. Current Drug Targets 4 (2003) 297-304
50. Sisodiya S.M., et al. Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy. Epilepsia 44 (2003) 1388-1396